-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the continuous improvement of the innovation strength of local pharmaceutical companies, China's contribution to global pharmaceutical innovation is also increasi.
Driven by multiple advantages such as policies, capital, and talents, the pace of domestic innovative drug listings has been accelerati.
For example, recently, the State Food and Drug Administration has successively approved the launch of a number of innovative products, including Velociguat tablets, intravascular imaging equipment and single-use intravascular imaging cathete.
In this regard, the industry believes that after years of policy support and R&D investment, China's pharmaceutical industry has gradually entered a period of innovation and harve.
Continuing the development trend in recent years, in 2021, the number of innovative drugs (referring to the drugs that are registered and classified as Class 1 or 1 approved by the National Medical Products Administration (NMPA) for marketing) will continue to grow, reaching 38, which is the same as the previous ye.
The sum of the four years is equivale.
Among the 38 innovative drugs, 34 are self-developed products, accounting for 847%, among which fumetinib, pamiparib, sevolitinib, vedicitumab, sapalimumab, sugar The 6 products of limumab have achieved "licence-out", which to a certain extent reflects the strength of China's pharmaceutical innovati.
It is understood that since the beginning of this year, pharmaceutical companies are still very active in the development of innovative dru.
For example, the biopharmaceutical industry is constantly setting off a wave of financi.
The data shows that in the first quarter, financing in China's biopharmaceutical field (excluding in vitro diagnostics and testing, e.
) was very active as a whole, with more than 90 Chinese biopharmaceutical companies completing financing of different rounds and natur.
It is worth mentioning that more than 50 new drug R&D companies have completed early-stage financing (A round/A+ round and befor.
Recently, a number of pharmaceutical companies have announced the completion of financing, which will be used for new drug development and promoti.
For example, a few days ago, Suzhou U-Synbio Technology .
, L.
(hereinafter referred to as "U-Synbio") announced the completion of tens of millions of angel round financi.
This round of financing is mainly used for the company's team development, laboratory construction, development of a series of pipeline products, as well as the optimization and upgrading of the core technology platform and external cooperati.
At present, many pharmaceutical companies have received good news about the approval of their products under the continuous high R&D investme.
For example, Hengrui Medicine has achieved fruitful results with high-intensity investme.
At present, the company has listed 10 innovative drugs, more than 60 innovative drugs are under clinical development, and more than 250 clinical trials are being carried out at home and abroad; BeiGene The financial report shows that as of April 15, 2022, the company has a total of 16 commercialized products on the mark.
Dozens of regulatory approvals have been achieved global.
It is worth mentioning that, with the continuous enhancement of the "self-hematopoietic" ability of China's local innovative pharmaceutical companies and the continuous improvement of the quality of innovative research and development, license out transactions are gradually becoming comm.
It is reported that on May 16, Kelun Pharmaceutical announced that Kelun Botai, a holding subsidiary of the company, licensed its biological macromolecular tumor project A with independent intellectual property rights to MSD (Merck & .
) for a fee outside of Chi.
commercial developme.
From the perspective of the industry, license out transactions represent the innovation capabilities of domestic new dru.
With the increase of license out transactions, it means that the innovation capabilities of domestic drugs are constantly improvi.
In the future, as domestic independent research and development enters the harvest period, more and more domestic innovative pharmaceutical companies are expected to accelerate the promotion of products overseas and promote international strategic layout in order to expand the market scope and better avoid the impact of medical insurance cost contr.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Driven by multiple advantages such as policies, capital, and talents, the pace of domestic innovative drug listings has been accelerati.
For example, recently, the State Food and Drug Administration has successively approved the launch of a number of innovative products, including Velociguat tablets, intravascular imaging equipment and single-use intravascular imaging cathete.
In this regard, the industry believes that after years of policy support and R&D investment, China's pharmaceutical industry has gradually entered a period of innovation and harve.
Continuing the development trend in recent years, in 2021, the number of innovative drugs (referring to the drugs that are registered and classified as Class 1 or 1 approved by the National Medical Products Administration (NMPA) for marketing) will continue to grow, reaching 38, which is the same as the previous ye.
The sum of the four years is equivale.
Among the 38 innovative drugs, 34 are self-developed products, accounting for 847%, among which fumetinib, pamiparib, sevolitinib, vedicitumab, sapalimumab, sugar The 6 products of limumab have achieved "licence-out", which to a certain extent reflects the strength of China's pharmaceutical innovati.
It is understood that since the beginning of this year, pharmaceutical companies are still very active in the development of innovative dru.
For example, the biopharmaceutical industry is constantly setting off a wave of financi.
The data shows that in the first quarter, financing in China's biopharmaceutical field (excluding in vitro diagnostics and testing, e.
) was very active as a whole, with more than 90 Chinese biopharmaceutical companies completing financing of different rounds and natur.
It is worth mentioning that more than 50 new drug R&D companies have completed early-stage financing (A round/A+ round and befor.
Recently, a number of pharmaceutical companies have announced the completion of financing, which will be used for new drug development and promoti.
For example, a few days ago, Suzhou U-Synbio Technology .
, L.
(hereinafter referred to as "U-Synbio") announced the completion of tens of millions of angel round financi.
This round of financing is mainly used for the company's team development, laboratory construction, development of a series of pipeline products, as well as the optimization and upgrading of the core technology platform and external cooperati.
At present, many pharmaceutical companies have received good news about the approval of their products under the continuous high R&D investme.
For example, Hengrui Medicine has achieved fruitful results with high-intensity investme.
At present, the company has listed 10 innovative drugs, more than 60 innovative drugs are under clinical development, and more than 250 clinical trials are being carried out at home and abroad; BeiGene The financial report shows that as of April 15, 2022, the company has a total of 16 commercialized products on the mark.
Dozens of regulatory approvals have been achieved global.
It is worth mentioning that, with the continuous enhancement of the "self-hematopoietic" ability of China's local innovative pharmaceutical companies and the continuous improvement of the quality of innovative research and development, license out transactions are gradually becoming comm.
It is reported that on May 16, Kelun Pharmaceutical announced that Kelun Botai, a holding subsidiary of the company, licensed its biological macromolecular tumor project A with independent intellectual property rights to MSD (Merck & .
) for a fee outside of Chi.
commercial developme.
From the perspective of the industry, license out transactions represent the innovation capabilities of domestic new dru.
With the increase of license out transactions, it means that the innovation capabilities of domestic drugs are constantly improvi.
In the future, as domestic independent research and development enters the harvest period, more and more domestic innovative pharmaceutical companies are expected to accelerate the promotion of products overseas and promote international strategic layout in order to expand the market scope and better avoid the impact of medical insurance cost contr.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
